Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.735 USD | +0.29% | -11.48% | -42.36% |
05-10 | Ocuphire Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-11 | Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment | MT |
Business Summary
Number of employees: 14
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Vision Performance and Health
100.0
%
| 40 | 100.0 % | 19 | 100.0 % | -52.20% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 40 | 100.0 % | 19 | 100.0 % | -52.20% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
George Magrath
CEO | Chief Executive Officer | 40 | 10-31 |
Nirav Jhaveri
DFI | Director of Finance/CFO | 46 | 02-13 |
Barbara Withers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Mitchell Brigell
CTO | Chief Tech/Sci/R&D Officer | - | - |
Joseph Schachle
COO | Chief Operating Officer | 59 | 11-26 |
Richard Rodgers
BRD | Director/Board Member | 57 | 20-10-31 |
Ronil Patel
PRN | Corporate Officer/Principal | - | 21-06-30 |
Erik Sims
PRN | Corporate Officer/Principal | - | 21-03-31 |
Drey Coleman
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | 68 | 17-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Rodgers
BRD | Director/Board Member | 57 | 20-10-31 |
James Manuso
BRD | Director/Board Member | 75 | 18-12-31 |
Susan Benton
BRD | Director/Board Member | 59 | 20-10-31 |
Cam Gallagher
CHM | Chairman | 54 | 18-12-31 |
Sean Ainsworth
BRD | Director/Board Member | 56 | 18-03-31 |
George Magrath
CEO | Chief Executive Officer | 40 | 10-31 |
Jay Pepose
BRD | Director/Board Member | 69 | 21-06-06 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 25,924,158 | 23,859,547 ( 92.04 %) | 0 | 92.04 % |
Company contact information
Ocuphire Pharma, Inc.
37000 Grand River Avenue Suite 120
48335, Farmington Hills
+
http://www.ocuphire.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.36% | 44.43M | |
+32.36% | 694B | |
+30.77% | 593B | |
-1.60% | 371B | |
+20.07% | 331B | |
+6.04% | 290B | |
+14.77% | 239B | |
+9.13% | 209B | |
-3.97% | 209B | |
+9.27% | 169B |
- Stock Market
- Equities
- OCUP Stock
- Company Ocuphire Pharma, Inc.